The Division of Gastroenterology and Hepatology, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
King Khalid University Hospital, King Saud University, P.O. Box 2925, Riyadh, 11461, Saudi Arabia.
BMC Complement Altern Med. 2019 Jan 17;19(1):21. doi: 10.1186/s12906-018-2409-0.
Peppermint oil (PO) has intrinsic properties that may benefit patients with irritable bowel syndrome (IBS) symptoms. The study objective was to determine the effect of peppermint oil in the treatment of the IBS.
We systematically searched MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (Cochrane CENTRAL), ClinicalTrials.gov, EMBASE (Ovid), and Web of Science for randomized controlled trials (RCTs) of PO for IBS. We appraised the eligible studies by the Cochrane risk of bias tool. We performed random-effects meta-analysis on primary outcomes including global improvement in IBS symptoms and abdominal pain. A PRISMA-compliant study protocol is registered in PROSPERO Register [2016, CRD42016050917].
Twelve randomized trials with 835 patients were included. For global symptom improvement, the risk ratio (RR) from seven RCTs for the effect of PO (n = 253) versus placebo (n = 254) on global symptoms was 2.39 [95% confidence interval (CI): 1.93, 2.97], I = 0%, z = 7.93 (p < 0.00001). Regarding abdominal pain, the RR from six RCTs for the effect of PO (n = 278) versus placebo (n = 278) was 1.78 [95% CI: 1.43, 2.20], I = 0%, z = 5.23 (p < 0.00001). Overall, there were no differences in the reported adverse effects: PO (32 events, 344 total, 9.3%) versus placebo (20 events, 327 total, 6.1%) for eight RCTs; RR 1.40 [95% CI: 0.87, 2.26] I = 0%, z = 1.39 (p = 0.16). The number needed to treat with PO to prevent one patient from having persistent symptoms was three for global symptoms and four for abdominal pain.
In the most comprehensive meta-analysis to date, PO was shown to be a safe and effective therapy for pain and global symptoms in adults with IBS.
薄荷油（PO）具有内在特性，可能有益于肠易激综合征（IBS）症状患者。本研究的目的是确定薄荷油在治疗 IBS 中的作用。
我们系统地检索了 MEDLINE（PubMed）、Cochrane 对照试验中心注册库（Cochrane CENTRAL）、ClinicalTrials.gov、EMBASE（Ovid）和 Web of Science 中的随机对照试验（RCT），以评估 PO 治疗 IBS 的效果。我们使用 Cochrane 偏倚风险工具评估合格研究。我们对主要结局（包括 IBS 症状和腹痛的整体改善）进行了随机效应荟萃分析。符合 PRISMA 标准的研究方案已在 PROSPERO 注册（2016 年，CRD42016050917）。
纳入了 12 项随机试验，共 835 名患者。对于整体症状改善，7 项 RCT 中 PO（n=253）与安慰剂（n=254）对整体症状的效果的风险比（RR）为 2.39[95%置信区间（CI）：1.93，2.97]，I=0%，z=7.93（p<0.00001）。关于腹痛，6 项 RCT 中 PO（n=278）与安慰剂（n=278）的 RR 为 1.78[95% CI：1.43，2.20]，I=0%，z=5.23（p<0.00001）。总体而言，报告的不良反应没有差异：8 项 RCT 中 PO（32 例事件，344 例总事件，9.3%）与安慰剂（20 例事件，327 例总事件，6.1%）；RR 1.40[95% CI：0.87，2.26]，I=0%，z=1.39（p=0.16）。需要 PO 治疗预防一名患者持续症状的患者人数为 3 人（全球症状）和 4 人（腹痛）。
在迄今为止最全面的荟萃分析中，PO 被证明是治疗成人 IBS 疼痛和整体症状的安全有效疗法。
